TRPV3通过氧化应激激活PARP1/AIFM1/MIF轴参与特应性皮炎
该研究揭示TRPV3功能获得性变异或药理激活可诱导PARP1/AIFM1/MIF轴介导的parthanatos(一种细胞死亡形式),且该过程通过钙介导的氧化应激调控。抑制PARP1可减轻MC903诱导的小鼠皮炎及Trpv3+/G568V小鼠的免疫浸润和表皮增厚,提示靶向该轴是Olmsted综合征和特应性皮炎的潜在疗法。
要点
- TRPV3激活通过钙-氧化应激诱导角质形成细胞parthanatos。
- PARP1抑制可下调TSLP/IL33并改善小鼠皮炎。
- 特应性皮炎患者皮肤中检测到明显parthanatos。
核心结论
- TRPV3调控的parthanatos相关PARP1/AIFM1/MIF轴是Olmsted综合征和特应性皮炎发病的关键因素。
研究设计与样本
- 研究使用Trpv3+/G568V小鼠、HaCaT细胞、MC903诱导的小鼠皮炎模型及特应性皮炎患者皮肤样本。
主要发现
- TRPV3功能获得性变异或药理激活导致PARP1/AIFM1/MIF轴介导的parthanatos。
- 螯合钙、清除ROS或抑制一氧化氮合酶可有效挽救parthanatos。
- 抑制PARP1下调HaCaT细胞中TRPV3激活诱导的TSLP和IL33。
- 抑制PARP1减少Trpv3+/G568V小鼠免疫细胞浸润并改善表皮增厚。
- MC903处理小鼠和特应性皮炎患者皮肤中检测到明显parthanatos,抑制PARP1大幅减轻MC903诱导的皮炎。
临床怎么用
- 调节PARP1/AIFM1/MIF轴可能成为Olmsted综合征和特应性皮炎的有前景疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TRPV3 is a temperature-sensitive calcium-permeable channel. In previous studies, we noticed prominent TUNEL-positive keratinocytes in patients with Olmsted syndrome and Trpv3+/G568V mice, both of which carry gain-of-function variants in the TRPV3 gene. However, it remains unclear how the keratinocytes die and whether this process contributes to more skin disorders. In this study, we showed that gain-of-function variant or pharmacological activation of TRPV3 resulted in poly(ADP-ribose) polymerase 1 (PARP1)/AIFM1/macrophage migration inhibitory factor axis-mediated parthanatos, which is an underestimated form of cell death in skin diseases. Chelating calcium, scavenging ROS, or inhibiting nitric oxide synthase effectively rescued the parthanatos, indicating that TRPV3 regulates parthanatos through calcium-mediated oxidative stress. Furthermore, inhibiting PARP1 downregulated TSLP and IL33 induced by TRPV3 activation in HaCaT cells, reduced immune cell infiltration, and ameliorated epidermal thickening in Trpv3+/G568V mice. Marked parthanatos was also detected in the skin of MC903-treated mice and patients with atopic dermatitis, whereas inhibiting PARP1 largely alleviated the MC903-induced dermatitis. In addition, stimulating parthanatos in mouse skin with methylnitronitrosoguanidine recapitulated many features of atopic dermatitis. These data demonstrate that the TRPV3-regulated parthanatos-associated PARP1/AIFM1/macrophage migration inhibitory factor axis is a critical contributor to the pathogenesis of Olmsted syndrome and atopic dermatitis, suggesting that modulating the PARP1/AIFM1/macrophage migration inhibitory factor axis is a promising therapy for these conditions.
引用
- Song Z, Gao M, Li T, et al. TRPV3-Activated PARP1/AIFM1/MIF Axis through Oxidative Stress Contributes to Atopic Dermatitis. J Invest Dermatol. 2024. PMID: 38823435. doi:10.1016/j.jid.2024.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。